tbuckley/cabot-search huggingface dataset:
Low-dose CT for the diagnosis of appendicitis in adolescents and young adults (LOCAT): a pragmatic, multicentre, randomised controlled non-inferiority trial
Authors: Hyuk Jung Kim, Byeong Geon Jeon, Chong Kun Hong, Kye Won Kwon, Seung Bong Han, Soya Paik, Suk Ki Jang, Young Rock Ha, Young Sik Kim, Min Hee Lee, Boem Ha Yi, Eung Jin Shin, Hae Kyung Lee, Hee Kyung Kim, Ho Jung Kim, Jae Hyung Choi, Young Soon Cho, Min-Jeong Kim, Dong Kyu Kim, Ji-Young Choe, Kyueng-Whan Min, Man Sup Lim, Sang Ook Ha, Sang Woo Lim, Youdong Sohn, Young Hwan Lee, Ji Hoon Park, Bon Seung Gu, Hye Seung Lee, Jae Hyuk Lee, Ji Ye Sim, Joonghee Kim, Kyoung Ho Lee, Kyuseok Kim, Soyeon Ahn, Sung-Bum Kang, Yoon Jin Lee, You Hwan Jo, Young Hoon Kim, Yousun Ko, Seung Joon Choi, Bohyung Song, Byung Ho Goh, Chaesuk Lim, Chang Rae Kim, Cho Rong Seo, Eunbaeck Kim, Gio Han, Jae-Hyug Woo, Jinhyun Kim, Kyoungjin Min, Min-A Lee, Min Ju Jeong, Min Kyoung Lee, Yong Su Lim, Young Sup Shim, Sung Bin Park, Chan Woong Kim, Dong Hoon Lee, Seung Eun Lee, Sung Eun Kim, Yoo Shin Choi, Sung Eun Rha, Eun Sun Jung, Gun Hyung Na, Han Joon Kim, Han Mo Yoo, Hye Kyung Chang, Joon Il Choi, Kyu Nam Park, Michael Yong Park, Moon Hyung Choi, Sang Hoon Oh, Seung Eun Jung, Sohee Lee, Soo Ah Im, Soo Hyun Kim, Soon Nam Oh, Tae Ho Hong, Won-Kyung Kang, Young Joon Lee, Young Hwan Lee, Dong Baek Kang, Hyun Soo Han, Jeong Woo Choi, Ki-Jung Yoon, Yong Hwang, Seong Sook Hong, Eui Sung Hwang, Heajin Chung, Hye Young Jang, Jiyoung Hwang, Jun Bum Park, Kyung Yul Hur, Yoon Mi Jeen, Young Joo Lee, Young Shin Cho, Han Jin Cho, Inyoung Choi, Jong Hak Park, Jooyeong Kim, Suk Keu Yeom, Sung Woo Moon, Young Sik Kim, Mi Sung Kim, Dong Hyuk Shin, Heon-Ju Kwon, Pil Cho Choi, Sang Kuk Han, Ji Young Woo, Gu Hyun Kang, Han Myun Kim, Hyun Young Choi, Ik Yang, Jae Ho Jang, Jeong Won Kim, Sang Nam Yoon, Won Hee Kim, Yong Soo Jang, Mi-Suk Park, In Cheol Park, Jae Gil Lee, Min Joung Kim, Yong Eun Chung, Jongmee Lee, Baek-Hui Kim, Chang Hee Lee, Jung-Youn Kim, Sanghee Kang, Sung-Hyuk Choi, Yang Shin Park, Seong Whi Cho, Chan Woo Park, Gi Bong Chae, Taek Guen Ohk, Yong-Hwan Jeon, Nurhee Hong, Dae Han Wi, Jun Hee Lee, Jung Nam Kwon, Seok Youn Lee, Weon-Cheol Han, Young Cheol Song, Mi Jeong Kim, Jung Hyeok Kwon, Seoung Kyu Beak, Sung Jin Kim, Woo Ik Choi, Yu Na Kang, Cheong-Il Shin, Dong Ho Lee, Gyeong Hoon Kang, Ijin Joo, Jeong Hee Yoon, Ji Won Park, Kyu Joo Park, Sang Do Shin, Seung-Bum Ryoo, Seung-Yong Jeong, Su Joa Ahn, Tae Han Kim, Won Chang, Yoon-Hye Kwon, Sang Soo Shin, Hee Joon Kim, Ho Goon Kim, Yong Soo Cho, Yoo Duk Choi, Bong Soo Kim, Chang Lim Hyun, Guk Myung Choi, In Ho Jeong, Kyeong Won Kang, Seung Hyoung Kim, Woo Jeong Kim, Young Joon Kang, Kwang Pyo Kim
Journal: The Lancet. Gastroenterology & hepatology (2017)
Abstract 15064: Control of Left Ventricular Load and Pulsatility by a Continuous-flow Left Ventricular Assist Device With a Native Heart Load Control System in Chronic Awake Phase
Authors: Kazuma Date, Takashi Nishimura, Satoru Kishimoto, Yoshiaki Takewa, Minoru Ono, Eisuke Tatsumi
Journal: Circulation (2014)

Introduction: We have previously developed a Native Heart Load Control System for a continuous-flow left ventricular assist device (EVAHEART) and demonstrated that the rotational speed (RS) in synchronization with the cardiac cycle can alter left ventricular (LV) load and pulsatility under general anesthesia. In this study, we assessed this system in chronic awake phase. Methods: We implanted EVAHEART in five goats (59.4±5.6kg) with a normal heart. Two weeks after the implantation, we examined the effects of the continuous mode (constant RS), counter-pulse mode (increase RS in diastolic phase) and co-pulse mode (increase RS in systolic phase) of this system on LV load and pulsatility in 100%, 75% and 50% bypass. We used two parameters to evaluate LV load, including stroke work (SW) and end-diastolic volume (LVEDV) determined from LV pressure-volume loops. About pulsatility, we used pulse pressure (PP) and mean dP/dt max of aortic pressure. Results: The co-pulse mode created greater LV load and pulsatility than the continuous mode in all bypass rates. In contrast, LV load and pulsatility in the counter-pulse mode were smaller than those in the continuous mode. There were statistically significant differences between values about LV load and pulsatility in counter-pulse and co-pulse mode; continuous/counter-pulse/co-pulse SW (ml·mmHg); 2601.71±2208.50/2127.88±1745.11/2845.54±2230.82 (100%): 2968.05±2265.75/2485.79±1714.07/3133.92±2203.64 (75%): 3134.42±2319.75/2927.76±2111.76/3313.13±2350.49 (50%), LVEDV (ml); 52.79±26.43/46.95±20.31/56.32±25.43 (100%): 57.22±28.19/51.38±21.83/59.06±26.63 (75%), 59.59±28.24/56.02±25.40/61.88±28.61 (50%), PP (mmHg); 30.09±10.01/22.63±8.09/36.79±9.32 (100%): 32.88±9.88/26.66±10.80/40.69±7.83 (75%): 37.30±10.86/32.76±12.43/41.97±9.59 (50%), mean dP/dt max of aortic pressure (mmHg/s); 979.89±369.20/687.98±230.12/1165.67±391.36 (100%): 1321.25±446.14/1047.78±393.29/1474.99±474.53 (75%): 1511.06±519.18/1332.6±471.91/1666.59±511.55 (50%). Conclusions: Our newly developed system could control LV load and pulsatility in the chronic awake phase. This system may provide the most favorable LV loading conditions for the recovery of the native heart.
New pediatric percentiles of liver enzyme serum levels (alanine aminotransferase, aspartate aminotransferase, γ‐glutamyltransferase): Effects of age, sex, body mass index, and pubertal stage
Authors: Sarah Bussler, Mandy Vogel, Diana Pietzner, Kristian Harms, Theresa Buzek, Melanie Penke, Norman Händel, Antje Körner, Ulrich Baumann, Wieland Kiess, Gunter Flemming
Journal: Hepatology (2017)

The present study aims to clarify the effects of sex, age, body mass index (BMI), and puberty on transaminase serum levels in children and adolescents and to provide new age- and sex-related percentiles for alanine aminotransferase (ALT), aspartate aminotransferase (AST), and γ-glutamyltransferase (GGT). Venous blood and anthropometric data were collected from 4,126 cases. Excluded were cases of participants with potential hepatotoxic medication, with evidence of potential illness at the time of blood sampling and non-normal BMI (BMI <10th or >90th). The resulting data (N = 3,131 cases) were used for the calculations of ALT, AST, and GGT percentiles. Age- and sex-related reference intervals were established by using an LMS method of Cole-type method. Serum levels of transaminases follow age-specific patterns and relate to the onset of puberty. This observation is more pronounced in girls than in boys. ALT percentiles showed similar-shaped patterns in both sexes. Multivariate regression confirmed significant effects of puberty and BMI-SDS (β = 2.21) on ALT. Surprisingly, AST serum levels were negatively influenced by age (β = -1.42) and BMI-SDS (β = -0.15). GGT percentiles revealed significant sex-specific differences, correlated positively with age (β = 0.37) and showed significant association with BMI-SDS (β = 1.16).Current reference values of ALT, AST, and GGT serum levels were calculated for children between 11 months and 16.0 years, using modern analytical and statistical methods. This study extends the current knowledge about transaminases by revealing influences of age, sex, BMI, and puberty on serum concentrations of all three parameters and has for these parameters one of the largest sample sizes published so far. (Hepatology 2017).
Saliva samples for genomic testing for preventive oncology: Improving the yield.
Authors: Christopher Manschreck, Kelly Lynn Stratton, John Sullivan, Kasmintan A. Schrader, Joseph Vijai, Kenneth Offit
Journal: Journal of Clinical Oncology (2013)

e12555 Background: Germline DNA procurement is an integral step in cancer genomic studies. Saliva collection has numerous benefits over blood draws, including lower cost, easier storage, less risk to patients, and ability to mail samples. However a major limitation to saliva is lower yield per extraction, limiting its use in whole genome sequencing studies. We present a modification of the standard protocol for extracting DNA from saliva collected in Oragene Discover 250 kits (DNA Genotek, Kanata, ON) that reduces both labor and reagent costs while providing yields sufficient for whole genome sequencing. Methods: Nineteen saliva samples were collected using the Oragene Discover 250 kit. Randomly, 10 were selected for extraction using the standard protocol. The remaining nine samples were allocated to the modified protocol. In the modified group, the cell mix was enriched by pelleting, removal of supernatant, followed by resuspension. At this point the sample was enriched for cellular material but at a volume suitable for processing according to the standard protocol. Standard quality control (QC) was performed using a spectrophotometer. Statistical analysis used Student’s T-test and Fisher’s Exact test. Results: All extracted samples attained appropriate quality measures with no significant difference between sample purities (mean 260:280 ratio: 1.72 vs 1.73). Samples undergoing modified extraction provided a mean concentration 50% higher than standard protocol (14.9 µg vs 9.9 µg, p=0.0038, 95% CI: 1.8 – 8.0). Comparing yields required to perform whole genome sequencing, the modified protocol provided significantly more samples meeting QC requirements (p=0.011). Conclusions: The advent of next generation sequencing has made DNA procurement vital to performing studies for preventive oncology. Noninvasive methods are preferred by patients and clinicians. Here we present a modification to a common DNA extraction protocol that provides labor and cost savings while producing sufficient yields for whole genome sequencing.
Identification of mutations in <i>SDR9C7</i> in six families with autosomal recessive congenital ichthyosis
Authors: A. Hotz, C. Fagerberg, A. Vahlquist, A. Bygum, H. Törmä, M.-A. Rauschendorf, H. Zhang, L. Heinz, E. Bourrat, I. Hausser, V. Vestergaard, A. Dragomir, A.D. Zimmer, J. Fischer
Journal: British Journal of Dermatology (2017)

Funding sources: Part of the study (J.F., M.‐A.R.) was supported by a grant from the German research foundation DFG (FI1767/3‐1), and by Swedish Research Council (K2013‐57X‐22309‐3) and HudFonden (802478‐8476, H.T., A.V.) Conflicts of interest: none declared. Dear Editor, Autosomal recessive congenital ichthyosis (ARCI) is a heterogeneous group of disorders of keratinization. To date, ARCI has been associated with the following genes: ABCA12, ALOX12B, ALOXE3, CERS3, CYP4F22, NIPAL4, TGM1, PNPLA1 and recently SDR9C7 and SULT2B1.1,2,3,4,5,6 Furthermore, seven patients from a large consanguineous family were described as having ARCI resulting from a homozygous mutation in LIPN;7 however, the first symptoms did not appear until the age of 5 years and the criterion of a congenital form of ichthyosis was not fulfilled. In this study, we report the clinical and molecular findings for seven patients with ARCI who carried five previously unreported mutations in SDR9C7. We could identify homozygous mutations in SDR9C7 using whole‐exome sequencing in three patients belonging to two families (P1‐1, P1‐2, P2). A subsequent screening of genetically unsolved ARCI cases revealed four additional patients (P3–P6) with mutations in SDR9C7 (reference sequence NM_148897.2).
Sulforaphane-Induced Cell Cycle Arrest and Senescence are accompanied by DNA Hypomethylation and Changes in microRNA Profile in Breast Cancer Cells
Authors: Anna Lewinska, Jagoda Adamczyk-Grochala, Anna Deregowska, Maciej Wnuk
Journal: Theranostics (2017)

Cancer cells are characterized by genetic and epigenetic alterations and phytochemicals, epigenetic modulators, are considered as promising candidates for epigenetic therapy of cancer.In the present study, we have investigated cancer cell fates upon stimulation of breast cancer cells (MCF-7, MDA-MB-231, SK-BR-3) with low doses of sulforaphane (SFN), an isothiocyanate.SFN (5-10 µM) promoted cell cycle arrest, elevation in the levels of p21 and p27 and cellular senescence, whereas at the concentration of 20 µM, apoptosis was induced.The effects were accompanied by nitro-oxidative stress, genotoxicity and diminished AKT signaling.Moreover, SFN stimulated energy stress as judged by decreased pools of ATP and AMPK activation, and autophagy induction.Anticancer effects of SFN were mediated by global DNA hypomethylation, decreased levels of DNA methyltransferases (DNMT1, DNMT3B) and diminished pools of N 6 -methyladenosine (m 6 A) RNA methylation.SFN (10 µM) also affected microRNA profiles, namely SFN caused upregulation of sixty microRNAs and downregulation of thirty two microRNAs, and SFN promoted statistically significant decrease in the levels of miR-23b, miR-92b, miR-381 and miR-382 in three breast cancer cells.Taken together, we show for the first time that SFN is an epigenetic modulator in breast cancer cells that results in cell cycle arrest and senescence, and SFN may be considered to be used in epigenome-focused anticancer therapy.
AB0684 Clinical response and radiographic progression in ankylosing spondylitis patients under anti-tnf therapy: impact of hip involvement
Authors: AY Shimabuco, FM Milanez, JCB Moraes, GV Perico, CR Gonçalves, MG Waisberg, PD Sampaio-barros, CGS Saad
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Hip involvement is considered an important prognostic factor associated with radiographic progression in ankylosing spondylitis (AS) patients. However, there are no studies regarding hip involvement impact on clinical response and radiographic progression in AS patients under anti-TNF therapy. <h3>Objectives</h3> Compare clinical and radiographic progression in AS patients receiving anti-TNF therapy with and without moderate-severe hip involvement. <h3>Methods</h3> Forty-seven AS patients referred to receive anti-TNF treatment were included and classified according to baseline hip involvement based on Bath Ankylosing Spondylitis Radiology Hip Index (BASRI-Hip): none-minimal hip disease (hip grade &lt;3) or moderate-severe disease (hip grade ≥3). Demographic data, presence of HLA-B27, extra-articular involvement, DMARD and NSAID use, clinical and laboratorial disease parameters (BASDAI, BASMI, BASFI, ASQol, mSASSS and inflammatory markers) were assessed at baseline and two years after anti-TNF treatment. <h3>Results</h3> Thirty-four (72.3%) patients were classified as none-minimal hip disease and 13 (27.7%) as moderate-severe hip involvement. Both groups were similar at baseline considering age, HLA-B27, extra-articular involvement and comedication use. Laboratorial markers (ESR, CRP) and disease parameters (BASDAI, BASFI and mSASSS) showed no difference at baseline. Moderate-severe group had longer disease (10.0±7.6 vs. 14.9±8.6, P=0.002, years), higher BASMI (3.8±2.4 vs. 6.5±2.5, P=0.002) and lower ASQoL (13.7±4.4 vs. 9.9±4.9, P=0.007). After two-years of anti-TNF therapy, both groups presented similar BASDAI response (delta BASDAI, p=0.134; final BASDAI, p=0.324) and an increase in mSASSS [no-minimal involvement: 13.6±18.3 vs. 16.1±19.4, P&lt;0.001); moderate-severe involvement: 21.7±19.9 vs. 28.6±18.5, P=0.003]. At final evaluation patients with moderate-severe hip involvement presented higher mSASSS (28.6±18.5 vs. 16.1±19.4, P=0.02), despite similar delta BASDAI and final BASDAI. <h3>Conclusions</h3> Our study provides evidence that hip involvement did not impact on clinical response in AS patients under anti-TNF therapy but may have an effect on radiographic progression of these patients. <h3>Disclosure of Interest</h3> None declared
Improving Asthma Care by Building Bridges Across Inpatient, Outpatient, and Community Settings
Authors: Sean M. Frey, Jill S. Halterman
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
AB0592 Pulmonary artery aneurysm in behÇet's disease: retrospective monocentric tunisian study
Authors: S Hammami, A Sondes, R Klii, M Kechida, M Ben Nasr, I Kochtali
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Behcet9s disease (BD) is a chronic inflammatory disorder. Arterial inflammatory involvement includes predominantly aortic and pulmonary aneurysmal lesions, affects about 10% of patients with BD. They account for the severity of the disease and are a leading cause of death <h3>Objectives</h3> To investigate the frequency of Behcet9s disease with pulmonary artery aneurysm (PAA). We aimed to review PAA and other systemic involvements associated with PAA in BD and to provide a review of diagnostic techniques, treatment and prognosis <h3>Methods</h3> 243 BD patients were recruited for this study (152 men, 91 women, mean age 31.7±7 years. Diagnosis of BD was made according to the international study group for Behçet9s disease [International Study Group for Behçet9s Disease, lancet 1990; 335: 1078–80]. All patients underwent full clinical examination, routine laboratory investigations. Chest X-rays and pulmonary CT angiography were performed on all patients with pulmonary involvement. <h3>Results</h3> Eight of the patients have pulmonary aneurysm, all of them are male, mean age 32.6±13, The mean disease duration until PAA appear was 2.8±3.5 years. The main pulmonary symptoms were as follows: dyspnea 87%, cough 50%, hemoptosis: 75%, fever 37%. Other systemic involvements associated PAA are as follows: buccal (100%) and genital (75%) ophthalmic 25%, neurological 50%, cardiac 25%. 3 patients presented with Hughes Stovin syndrome. The treatment includes corticosteroids, colchicine and immunosuppressant agents (Cyclophosphamid or azathioprine), only two patients reveive coil embolization. At follow up for a median of 4 years (1 to 25 years), three patients died because they stopped their medication. <h3>Conclusions</h3> The prognosis of PAA is poorer than other lesions involved in BD, treatment (immunosuppressant agents, colchicine) seems to improve the prognosis. It is important to maintain the immunosuppressive therapy and a regular follow-up to prevent these complications <h3>References</h3> Desbois AC et al Aortic inflammatory lesions in Behçet9s disease Rev Med Interne. 2016 Apr;37(4):230–8. Celik S et al. Pulmonary artery aneurysms in Behçet9s syndrome: a review of the literature with emphasis on geographical differences. Clin Exp Rheumatol. 2015 Nov-Dec;33(6 Suppl 94):S54–9. <h3>Disclosure of Interest</h3> None declared
GRK2 Is a Novel Modulator of the MALT1 Oncoprotein
Authors: Jing Cheng, Heejae Kang, Narayanan Parameswaran, Mathijs Baens, Ming Zhang, Phillip C Delekta, Nathaniel E Hubel, Vincent Jonathan Concel, Margot Thome, Peter C Lucas, Linda McAllister-Lucas
Journal: Blood (2016)
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?
Authors: Velia Chiara Di Maio, Valeria Cento, Marianna Aragri, Stefania Paolucci, Teresa Pollicino, Nicola Coppola, Bianca Bruzzone, Valeria Ghisetti, Maurizio Zazzi, Maurizia Brunetto, Ada Bertoli, Silvia Barbaliscia, Silvia Galli, William Gennari, Fausto Baldanti, Giovanni Raimondo, Carlo Federico Perno, Francesca Ceccherini-Silberstein, Pietro Andreone, Massimo Andreoni, Mario Angelico, Sergio Babudieri, Giorgio Barbarini, Vincenzo Boccaccio, Lucio Boglione, Matteo Bolis, Stefano Bonora, Vanni Borghi, Giuseppina Brancaccio, Savino Bruno, Pierluigi Cacciatore, Vincenza Calvaruso, Nicola Caporaso, Antonio Ciaccio, Alessia Ciancio, Piero Colombatto, Raffaele Cozzolongo, Antonio Craxì, Cecilia D'Ambrosio, Gabriella D'Ettorre, Andrea De Luca, Antonio Di Biagio, Giovanni Di Perri, Simona Francioso, Giovanni Battista Gaeta, Alessia Giorgini, Antonio Grieco, Guido Gubertini, Roberto Gulminetti, Lara Lambiase, Ilaria Lenci, Miriam Lichtner, Ivana Maida, Simona Marenco, Letizia Marinaro, Renato Maserati, Chiara Masetti, Michela Melis, Elisa Meregalli, Valeria Micheli, Filomena Morisco, Fosca Niero, Laura Ambra Nicolini, Valeria Pace Palitti, Maurizio Paoloni, Giustino Parruti, Caterina Pasquazzi, Adriano Pellicelli, Ennio Polilli, Maria Laura Ponti, Massimo Puoti, Maria Rendina, Giuliano Rizzardini, Barbara Rossetti, Tina Ruggiero, Vincenzo Sangiovanni, Mario Starace, Laura Sticchi, Pierluigi Tarquini, Pierluigi Toniutto, Vincenzo Vullo
Journal: Journal of Hepatology (2017)
Multimodal Assessment of Mesenchymal Stem Cell Therapy for Diabetic Vascular Complications
Authors: Jamila Hedhli, Christian J. Konopka, Sarah Schuh, Hannah Bouvin, John A. Cole, Heather D. Huntsman, Kristopher A. Kilian, Iwona T. Dobrucki, Marni D. Boppart, Lawrence W. Dobrucki
Journal: Theranostics (2017)

Peripheral arterial disease (PAD) is a debilitating complication of diabetes mellitus (DM) that leads to thousands of injuries, amputations, and deaths each year. The use of mesenchymal stem cells (MSCs) as a regenerative therapy holds the promise of regrowing injured vasculature, helping DM patients live healthier and longer lives. We report the use of muscle-derived MSCs to treat surgically-induced hindlimb ischemia in a mouse model of type 1 diabetes (DM-1). We serially evaluate several facets of the recovery process, including αVβ3 -integrin expression (a marker of angiogenesis), blood perfusion, and muscle function. We also perform microarray transcriptomics experiments to characterize the gene expression states of the MSC-treated is- chemic tissues, and compare the results with those of non-ischemic tissues, as well as ischemic tissues from a saline-treated control group. The results show a multifaceted impact of mMSCs on hindlimb ischemia. We determined that the angiogenic activity one week after mMSC treatment was enhanced by approximately 80% relative to the saline group, which resulted in relative increases in blood perfusion and muscle strength of approximately 42% and 1.7-fold, respectively. At the transcriptomics level, we found that several classes of genes were affected by mMSC treatment. The mMSCs appeared to enhance both pro-angiogenic and metabolic genes, while suppressing anti-angiogenic genes and certain genes involved in the inflammatory response. All told, mMSC treatment appears to exert far-reaching effects on the microenvironment of ischemic tissue, enabling faster and more complete recovery from vascular occlusion.